Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India · Delayed Price · Currency is INR | Market Cap | 316.45B +9.8% |
| Revenue (ttm) | 28.91B +14.3% |
| Net Income | 5.42B +5.6% |
| EPS | 32.40 +5.4% |
| Shares Out | 167.06M |
| PE Ratio | 58.46 |
| Forward PE | 47.91 |
| Dividend | 20.00 (1.05%) |
| Ex-Dividend Date | Jul 30, 2026 |
| Volume | 99,702 |
| Open | 1,894.00 |
| Previous Close | 1,889.40 |
| Day's Range | 1,880.00 - 1,914.80 |
| 52-Week Range | 1,272.60 - 1,988.90 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 1,927.85 (+1.78%) |
| Earnings Date | Jul 24, 2026 |
About Dr. Lal PathLabs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]
Financial Performance
In fiscal year 2026, Dr. Lal PathLabs's revenue was 27.63 billion, an increase of 12.25% compared to the previous year's 24.61 billion. Earnings were 5.05 billion, an increase of 3.62%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for LALPATHLAB stock is "Buy." The 12-month stock price target is ₹1,928, which is an increase of 1.78% from the latest price.
News
Dr. Lal PathLabs Transcript: Q1 26/27
Q1 FY27 saw 19.1% revenue growth, driven by higher patient volumes, improved realizations, and strong Swasthfit and Suburban performance. EBITDA margin reached 31%, with robust cash reserves and continued investment in innovation and expansion.
Dr. Lal PathLabs Quarterly report: Q1 2027
Dr. Lal PathLabs has published its Q1 2027 quarterly earnings report on July 24, 2026.
Dr. Lal PathLabs Slides: Q1 2027
Dr. Lal PathLabs has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 24, 2026.
India's Dr Lal PathLabs posts higher first-quarter profit on healthy demand for tests
Indian diagnostics firm Dr Lal PathLabs on Friday reported a rise in first-quarter profit, boosted by sustained demand for its tests and preventive health packages under the SwasthFit banner.
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q1 2027 Earnings Report Preview: What to Expect
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q1 2027 Earnings Report Preview: What to Expect
Dr. Lal PathLabs Earnings Call Transcript: Q4 2026
FY 2026 saw double-digit revenue and EBITDA growth, driven by volume gains, network expansion, and strong B2C performance. Outlook for FY 2027 is early to mid-teens revenue growth with stable margins, supported by continued investment and broad-based regional momentum.
Dr. Lal PathLabs Quarterly report: Q4 2026
Dr. Lal PathLabs has published its Q4 2026 quarterly earnings report on April 30, 2026.
Dr. Lal PathLabs Slides: Q4 2026
Dr. Lal PathLabs has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
Dr. Lal PathLabs Annual report: Q4 2026
Dr. Lal PathLabs has published its Q4 2026 annual report on April 30, 2026.
Dr Lal PathLabs records Rs 703 Cr revenue with 16.6% growth in Q4 FY26
Dr Lal PathLabs Limited, a prominent diagnostic and healthcare service provider, has announced its financial results for the quarter ending March 31, 2026. The company reported a revenue of ₹703…
Dr Lal Pathlabs Q4 Results: Profit falls 15% as margin declines nearly 300 bps
Dr Lal PathLabs reported a decline in profitability for the quarter ended March 31, 2026, even as revenue posted steady growth. Revenue from operations rose 16.60% year-on-year (YoY) to ₹702.70…
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q4 2026: Everything You Need to Know Ahead of Earnings
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q4 2026: Everything You Need to Know Ahead of Earnings
Petronet LNG, HDFC Bank & more: Top stocks to watch today
Nomura cut Petronet LNG's target price due to West Asia crisis impacting volumes, while HSBC maintained a hold on Blue Star, citing demanding valuations. BofA Securities remains constructive on HDFC B...
Dr Lal PathLabs share in focus as CLSA sees ~17% upside on volume-led growth
Shares of Dr Lal PathLabs are in focus after CLSA maintained an Outperform rating on the stock with a target...
Dr. Lal PathLabs Transcript: Q3 25/26
Revenue grew 10.6% YoY in Q3 FY26, with strong EBITDA margin of 27.2% and robust cash reserves. Preventive health packages and digital innovation drove growth, while a one-time Labour Code cost impacted PAT. Management expects stable margins and organic growth ahead.
Dr. Lal PathLabs Quarterly report: Q3 2026
Dr. Lal PathLabs has published its Q3 2026 quarterly earnings report on January 30, 2026.
Dr. Lal PathLabs Slides: Q3 2026
Dr. Lal PathLabs has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 30, 2026.
Earnings To Watch: Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Reports Q3 2026 Result
Earnings To Watch: Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Reports Q3 2026 Result
Dr. Lal PathLabs fixes December 19 as record date for 1:1 bonus issue
Dr. Lal PathLabs Ltd has announced that its Board of Directors has fixed Friday, December 19, 2025, as the record...
Dr. Lal PathLabs Transcript: Q2 25/26
Revenue grew 10.7% YoY in Q2 FY26 with strong profitability and a PAT increase of 16.4%. Investments in digital, AI, and high-end diagnostics, along with disciplined network expansion, are driving growth. Interim dividend and a 1:1 bonus issue were announced.
Dr. Lal PathLabs Quarterly report: Q2 2026
Dr. Lal PathLabs has published its Q2 2026 quarterly earnings report on October 31, 2025.
Dr. Lal PathLabs Slides: Q2 2026
Dr. Lal PathLabs has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 31, 2025.
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 2026 Earnings Report Preview: What To Expect
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 2026 Earnings Report Preview: What To Expect
Dr. Lal PathLabs Transcript: Q1 25/26
Q1 FY26 saw 11.3% revenue growth and 24.3% profit after tax increase, driven by higher volumes, favorable test mix, and expansion in bundled and specialized testing. Guidance for 11–12% revenue growth is maintained, with margins expected to remain strong.
Dr. Lal PathLabs Quarterly report: Q1 2026
Dr. Lal PathLabs has published its Q1 2026 quarterly earnings report on July 31, 2025.